Home » Newsletters » BioWorld

BioWorld

Jan. 30, 1992

View Archived Issues

ATHENA TOXIN DESIGNATED ORPHAN

ANALYST RECOMMENDS IDEXX

BAXTER PLANS BONE MARROW TRIALS

IMMUNEX MARKETING DEAL

ONCOR RAISES $31.5 MILLION IN SECONDARY

PDL IPO BRINGS IN $52.5 MILLION

INITIATIVE PROPOSES 7% HIKE IN FUNDING

BUSH BUDGET'S IMPACT ON BIOTECH

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...